Stocktoria
Bone Biologics Corp BBLG
Bone Biologics Corp (BBLG) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BBLG | Bone Biologics Corp | 3/9 | — | — | +0% |
| ISRG | INTUITIVE SURGICAL INC | 6/9 | 12.06 | 50.2 | +20.5% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | 5/9 | 3.96 | 24.5 | +7.2% |
| EW | Edwards Lifesciences Corp | 6/9 | 9.6 | 48.7 | +11.5% |
| STE | STERIS plc | 9/9 | 4.5 | 26.9 | +8.7% |
| ALGN | ALIGN TECHNOLOGY INC | 6/9 | 4.56 | 31.1 | +0.9% |
| ENOV | Enovis CORP | 4/9 | -1.51 | — | +6.7% |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
FAQ
Is BBLG financially healthy?
Bone Biologics Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does BBLG pay a dividend?
No, Bone Biologics Corp does not currently pay a dividend.
How profitable is BBLG?
In FY2025, Bone Biologics Corp had a return on equity of -57.8%.
What is the analyst price target for BBLG?
The average Wall-Street price target for Bone Biologics Corp is $22.20, about 3273.9% above the recent price, from 1 analysts.
Is BBLG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Bone Biologics Corp: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.